Abstracts tagged "Lupus nephritis"

Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Peter Yorgin¹, Suhas Radhakrishna¹, Caitlin Carter¹, Johanna Chang¹, Katayoon Shayan¹, Lieuko Nguyen¹, Peter Chiraseveenuprapund¹ and Robert Sheets², ¹UCSD/Rady Children's Hospital, San Diego, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…
Abstract Number: 1836 • ACR Convergence 2020
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Zahir Amoura¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Dario Roccatello⁶, Richard Furie⁷, Thomas Schindler⁸, Jay Garg⁹, Matthew Cascino⁹, Brad Rovin¹⁰ and Andrea Doria¹¹, ¹Hôpital Pitié-Salpêtrière, Paris, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶S Giovanni Hospital, Univ of Turin, Turin, Italy, ⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰The Ohio State University, Columbus, ¹¹University of Padua, Padua, Italy
Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
Abstract Number: 0288 • ACR Convergence 2020
Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus
Sule Yavuz¹, Pascal Pucholt², Dag Leonard², Juliana Imgenberg-Kreuz², Matteo Bianchi², Johanna Sandling², Iva Gunnarsson³, Swedish Sle Network² and Lars Ronnblom², ¹Uppsala University Rheumatology, Doral, FL, ²Uppsala University, Uppsala, Sweden, ³Karolinska Institute, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is a common debilitating manifestation of Systemic Lupus Erythematosus (SLE). Despite improved understanding of underlying mechanisms driving to LN and early…
Abstract Number: 0979 • ACR Convergence 2020
The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW
Paul Hoover¹, Michael Peters², David Lieb³, Heather Geiger⁴, Rakesh Mishra⁵, Nir Hacohen² and Anne Davidson⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, ³Broad Institute, Boston, MA, ⁴New York Genome Center, New York, NY, ⁵Feinstein Institute, Manhasset, NY, ⁶Northwell Health, New York
Background/Purpose:Poor renal prognosis in lupus nephritis (LN) is associated with an abundance of renal macrophages and dendritic cells (DCs) but the role of these cells…
Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Verena Balbi¹, Clovis Silva², Tatiana Pedrosa³, Rosa Pereira³, Lucia Campos³, Elaine Leon³, Nilo Duarte³, Valdemir Carvalho⁴, Sandra Pasoto³, Debora Rosario³, Leticia Brandao³, Eloisa Bonfa³ and Nadia Aikawa³, ¹Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, ²Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…
Abstract Number: 1843 • ACR Convergence 2020
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Ellen M Ginzler¹, Joshua Kaplan², Laura Lisk³, Ray Federico⁴, Neil Solomons⁵ and Robert Huizinga⁵, ¹SUNY Downstate Health Sciences University, Brooklyn, ²Rutgers University, New Brunswick, NJ, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁴Aurinia Pharmaceuticals, Inc., Victoria, Canada, ⁵Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
Abstract Number: 0289 • ACR Convergence 2020
Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, W. Winn Chatham¹, Hui-Chen Hsu¹ and John Mountz², ¹University of Alabama at Birmingham, Birmingham, AL, ²University Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: We previously showed that B-cell endogenous interferon-beta (IFNβ) at the transitional (Tr) stage correlates with development of anti-Smith (anti-Sm) and renal disease as well…
Abstract Number: 0980 • ACR Convergence 2020
Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time-trends, Healthcare Utilization and In-Hospital Mortality
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To examine the time-trends in hospitalized infections in lupus and the factors associated with healthcare utilization and in-hospital mortality.Methods: We used the U.S. National…
Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Kelly Rouster-Stevens², Marisa Klein-Gitelman³, Karen Onel⁴, Beatrice Goilav⁵, Sonia Savani⁶, Natasha Ruth⁶, Tingting Qiu⁷, Najla Aljaberi⁸, Jianghong Deng⁹, Angela Merritt⁸, Benjamin Laskin¹⁰, Anna Carmela Sagcal-Gironella¹¹, Stacy Ardoin¹², Deborah Levy¹³, Scott Wenderfer¹⁴, Bin Huang⁷, Hermine I Brunner¹⁵ and LaUNCH Project Investigators¹⁶, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Beijing Children’s Hospital, Beijing, China (People's Republic), ¹⁰Children's Hospital of Philadelphia, Philadelphia, ¹¹Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, ¹²Nationwide Children's Hospital, Columbus, OH, ¹³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁶LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
Abstract Number: 0598 • ACR Convergence 2020
Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality
Shivani Garg¹, Callie Plafkin², Tripti Singh¹, Sarah Panzer³ and Christie Bartels⁴, ¹UW Madison, Madison, WI, ²UW Madison, Madison, ³UW-Madison, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Lupus nephritis (LN) contributes to a 10-fold higher risk to develop kidney failure and 26-fold higher mortality compared to peers. Kidney biopsy remains a…
Abstract Number: 0988 • ACR Convergence 2020
Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis
Richard Furie¹, Gustavo Aroca², Analia Alvarez³, Hilda Fragoso-Loyo⁴, Elizabeth Zuta Santillan⁵, Brad Rovin⁶, Paul Brunetta⁷, Thomas Schindler⁸, Imran Hassan⁹, Matthew Cascino¹⁰, Jay Garg¹⁰ and Ana Malvar¹¹, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, ³CEMIC, Buenos Aires, Argentina, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Instituto de Ginecología y Reproducción, Lima, Peru, ⁶The Ohio State University, Columbus, ⁷Genentech, Inc., South San Francisco, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Hoffmann-La Roche Ltd, Mississauga, Canada, ¹⁰Genentech, Inc., South San Francisco, CA, ¹¹Organizacion Medica de Investigacion, Buenos Aires, Argentina
Background/Purpose: NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through…
Abstract Number: 1789 • ACR Convergence 2020
Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Vitamin D is correctly classified as a sterol-hormone rather than a vitamin (Semin Nephrol 1986;6:4-20). It has multiple immunomodulatory effects, as well as cardiovascular…
Abstract Number: 0838 • ACR Convergence 2020
T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis
Milena Vukelic¹, Masataka Umeda¹, Andrew Ferretti², Rhea Bhargava¹, Nobuya Yoshida¹ and George Tsokos³, ¹Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center Harvard Medical School, Boston, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production, immune complex deposition and multisystem involvement. Calcium/calmodulin-dependent protein kinase type IV…

1
2
3
…
16
Next Page »